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Mutations in SLC12A5 in epilepsy of infancy with
migrating focal seizures
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Irene Farabella10, Esther Meyer3, Atsuo Kawahara11, Grace Vassallo12, Stavros M. Stivaros13,14,
Magnus K. Bjursell15,w, Henrik Stranneheim15,16, Stephanie Tigerschio¨ld15,16, Bengt Persson17,18,
Iftikhar Bangash19, Krishna Das4,20, Deborah Hughes21, Nicole Lesko16,22, Joakim Lundeberg23,
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Anna Wedell15,16,** & Manju A. Kurian3,4,**
The potassium-chloride co-transporter KCC2, encoded by SLC12A5, plays a fundamental role
in fast synaptic inhibition by maintaining a hyperpolarizing gradient for chloride ions. KCC2
dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related
epilepsy disorders have been described. Here we show recessive loss-of-function SLC12A5
mutations in patients with a severe infantile-onset pharmacoresistant epilepsy syndrome,
epilepsy of infancy with migrating focal seizures (EIMFS). Decreased KCC2 surface expres-
sion, reduced protein glycosylation and impaired chloride extrusion contribute to loss of
KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excit-
ability in this early-onset epileptic encephalopathy.
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E
pilepsy of infancy with migrating focal seizures (EIMFS)
is an early-infantile epileptic encephalopathy (EIEE)
previously known as migrating partial seizures of infancy.
It is characterized by multifocal seizures, developmental arrest or
regression and a distinct ictal pattern on electroencephalogram
(EEG)1,2. EIMFS is genetically heterogeneous1–3 (Supplementary
Table 1) and the underlying cause remains elusive for many
affected infants1.
In this study, we report a novel genetic cause of EIMFS,
identifying recessive SLC12A5 mutations in four affected children
from two unrelated families. SLC12A5 encodes the potassium-
chloride co-transporter KCC2, which plays an integral role in
neuronal inhibition4–7 and maturation of cortical dendritic
spines8. We demonstrate that the identiﬁed mutants negatively
impact KCC2 protein expression and glycosylation, with
impaired KCC2-mediated chloride extrusion.
Results
Recessive SLC12A5 mutations in patients with EIMFS. From a
cohort of 42 patients (39 families) with EIMFS, we identiﬁed two
families, one kindred of Swedish origin (Family A, unrelated
asymptomatic parents) and one of Pakistani descent (Family B,
consanguineous ﬁrst cousin healthy parents). Each family had
two affected children who developed clinical features of EIMFS
(Fig. 1a). All four patients presented similarly with infantile-onset
focal migrating seizures, with rapid escalation to a severe
pharmacoresistant epileptic disorder (Supplementary Note 1).
Interictal multifocal epileptiform discharges were observed on
EEG, and ictal activity migrating from one hemisphere to the
other was recorded (Fig. 1b). In all cases, there was signiﬁcant
neurological regression leading to severe developmental delay.
One patient died (at the age of 2.5 years) due to secondary
cardiorespiratory complications (Supplementary Note 1,
Supplementary Fig. 1).
Using an autozygosity mapping strategy in kindred B, and
exome sequencing in both Families A and B, we identiﬁed
monogenic recessive SLC12A5 mutations in all affected children
with EIMFS. Exome sequencing for both parents and children of
Family A was undertaken and all variants scored and ranked
using the Mutation Identiﬁcation Pipeline weighted sum model
(Supplementary Table 2) that uses multiple parameters, but
emphasizes Mendelian inheritance patterns, conserved, rare and
protein damaging variants. This left only one gene, SLC12A5,
with adequate coverage in all individuals sequenced that
conformed to autosomal recessive inheritance (Supplementary
Table 3a). For Family B, single-nucleotide polymorphism (SNP)
array analysis revealed seven common regions of homozygosity
(6–43Mb in size) in the affected children (Supplementary
Table 3b). Stringent ﬁltering for homozygous, potentially
pathogenic variants within these homozygous regions identiﬁed
four genes, of which, after detailed analysis (Supplementary
Methods, Supplementary Table 3b) SLC12A5 was deemed by far
the most biologically plausible candidate for this phenotype.
Results from exome analysis were conﬁrmed on direct Sanger
sequencing. The children from Family A were conﬁrmed
compound heterozygotes for missense mutations c.1277T4C
(L426P) and c.1652G4A (G551D), while the two affected
patients from Family B were homozygous for the missense
variant c.932T4A (L311H) (Fig. 1c,d). All mutations showed
appropriate familial disease segregation (parents were hetero-
zygous carriers) and were not reported in healthy control
populations (dbSNP137, 1000 Genomes SNP calls and the
NHLBI Exome Sequencing Project). Affected amino acids were
highly conserved across species (Supplementary Fig. 2). In both
families, no potentially pathogenic variants were found in other
genes known to cause EIMFS or EIEE. A further 38 patients
(from 37 families) with EIMFS were screened for mutations in
SLC12A5 and no mutations were identiﬁed (Supplementary
Methods). There were no discernible phenotypic differences
between the SLC12A5 mutation-positive and mutation-negative
patients.
KCC2 mediates physiological neuronal chloride extrusion.
KCC2 is a membrane protein located at the somatodendritic cell
compartment of mature neurons4. KCC2 is exclusively expressed
in the central nervous system, including neurons in all layers of
the neocortex, CA1-4 subﬁelds of the hippocampus and
cerebellum4,5. In mature neurons, KCC2 is the major extruder
of intracellular chloride and in the presence of low intraneuronal
chloride levels, the binding of GABA (g-aminobutyric acid) and
glycine to their ionotropic receptors results in chloride inﬂux
with subsequent hyperpolarization contributing to neuronal
inhibition4,5. During brain development, the neuronal chloride
equilibrium potential (ECI) gradually hyperpolarizes, in parallel
with upregulation of KCC2, which contributes to the
establishment and maintenance of hyperpolarizing inhibitory
post-synaptic potentials6,7. Recent evidence additionally implicates
KCC2 as a structural protein involved in the morphological and
functional maturation of cortical dendritic spines8. A number of
further investigations were therefore undertaken to elucidate the
impact of the identiﬁed mutations on KCC2 function.
Homology modelling for identiﬁed KCC2 mutants. KCC2
exists in both monomeric and oligomeric forms9, and consists of
12 transmembrane (TM) helices interconnected by a series of
extracellular and intracellular loops (Figs 1d,2a). Alternative
splicing gives rise to two isoforms KCC2a and KCC2b, differing
by an extra 40 amino acids in the N-terminus of KCC2b. The
changes identiﬁed in our patients are present in both isoforms,
and protein homology modelling studies were undertaken to
predict damaging effects on the structure-function properties of
KCC2 (Fig. 2a-c). Located within TM6, L426 is almost universally
conserved in the 100 most similar proteins and substitution with
a proline residue is expected to disrupt this TM helix (Fig. 2b).
G551, located in the intracellular loop between TM8–TM9
(Fig. 2c), is also well conserved in similar proteins, and
substitution with the signiﬁcantly larger negatively charged
aspartate residue may interact unfavourably with other residues
in the loop region or block other molecular interactions. L311H is
located extracellularly between TM5 and TM6 and the extended
loop region between residues 303 and 407 is not amenable to
accurate modelling because of lack of sequence identity. Most
KCC2 homologues have a hydrophobic residue at this position
311 (typically valine, methionine, isoleucine or phenylalanine), and
a leucine/histidine exchange would therefore be expected to break
hydrophobic interactions, thereby disrupting structural stability of
the TM5–TM6 loop. L311 is also adjacent to one of four
evolutionarily conserved cysteines (C310, C325, C345 and C354)
in the TM5–TM6 region that are vital for KCC2 transport
activity10. L311 may be part of a hydrophobic pocket formed with
a cysteine disulphide bond, in which case L311H may also interfere
with the formation of intra- or intermolecular disulphide bonds.
KCC2 mutants affect chloride homeostasis. To investigate the
functional consequences of the identiﬁed mutations on KCC2
transporter function and chloride (Cl ) homeostasis, we recor-
ded in voltage-clamp mode from HEK293 cells transiently
transfected with enhanced green ﬂuorescent protein (eGFP) and
the glycine receptor (GlyR) a2 subunit, which forms homo-
pentameric glycine-gated chloride channels11. Recordings were
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Figure 1 | Clinical and molecular genetic ﬁndings in families with EIMFS. (a) Family A (Caucasian origin) and Family B (Pakistani origin). Squares
represent males. Circles represent females. Affected individuals are represented by black shading. Double parallel horizontal bars indicate consanguinity in
Family B. (b) The left upper and lower EEG recording are two consecutive EEG segments, each 1min long, from the ictal EEG of proband A-II:1. Seizure
activity is boxed in black with rhythmic spike-waves evident initially on the left hemisphere (red), then fading and seizure activity starting up in the right
(blue) temporal area. Expanded segments below (10 s) show the spike-wave activity in more detail. Montage: Longitudinal bipolar according to the 10–20
system. Only lateral channels shown. The right upper (compressed) and lower EEG recording from proband B-II:4 reveal central/vertex and right parietal
epileptiform activity (purple/red and boxed in red, upper right ﬁgure) that wanes with a return to the interictal state before onset of left centro-temporal
ictal activity associated with facial twitching (blue and boxed in red, lower right ﬁgure). (c) SLC12A5 consists of 26 exons (purple rectangles). Both wild-type
(WT) and mutant DNA sequence is displayed. Three point mutations were identiﬁed in four patients with EIMFS (WTsequence indicated by yellow arrow,
mutated base by orange arrow). The children from Family A harboured missense mutations in exon 9 (c.1277T4C, L426P) and 13 [c.1652G4A, G551D],
while the two affected Family B patients were homozygous for missense variant c.932T4A (L311H) in exon 8. (d) The KCC2 protein structure consists of 12
transmembrane (TM) helices (numbered blue cylinders) interconnected by a series of extracellular and intracellular loops. Sites of phosphorylation at the
C-terminus are depicted as light green hexagons. N-linked glycosylated sites are indicated as dark green Y-shaped structures present at the extracellular
loop between TM5 and TM6. The EIMFS mutations are indicated in red circles, located in the extracellular loop between TM5 and TM6 (L311H), within
TM6 (L426P) and in the intracellular loop between TM8 and TM9 (G551D). Variants associated with idiopathic generalized epilepsy and febrile
convulsions are represented as purple circles at the C-terminus.
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also obtained from cells co-transfected with a plasmid either
encoding the wild-type KCC2b isoform or one of the mutants
L311H, L426P and G551D. Pressure application of glycine evoked
large inward currents (IGly) in eGFP-positive cells held at –80mV
(n¼ 33), but not in eGFP-negative cells (n¼ 8). The IGly
amplitude varied linearly with the holding potential and
reversed in polarity. Fitting the I–V relationship, cells
transfected with both GlyR a2 and wild-type KCC2 yielded a
more hyperpolarising ECl than cells solely expressing GlyR a2
(Fig. 3a), consistent with Cl extrusion by KCC2. KCC2
mutants, however, exhibited a depolarized ECl relative to wild-
type KCC2 (Fig. 3b). The estimated ECl for all three mutants was
similar and did not differ signiﬁcantly from that in cells solely
expressing GlyR a2 and eGFP (Fig. 3c), consistent with passive
equilibration of Cl ions as predicted from the pipette and
extracellular solutions. To further explore impaired mutant KCC2
activity, we measured the rate at which ECl recovers to a starting
value after a period of chloride load, as described previously12.
Glycine was applied every 30 s while holding cells at  80mV
then at þ 40mV to load them with Cl (Fig. 3d). When the
holding potential was reset to  80mV, glycine-evoked currents
were larger due to the increased driving force. In cells transduced
with wild-type KCC2, glycine-evoked currents IGly returned to the
initial amplitude consistent with transporter-mediated extrusion
of chloride. The rate at which IGly amplitude recovered for the
three KCC2 mutants was much slower (Fig. 3e,f). The recovery
rate in cells expressing L426P and G551D mutants was not
signiﬁcantly different from cells expressing only GlyR a2 and
eGFP, consistent with near complete loss of KCC2 function. The
recovery rate for the L311H mutant was intermediate, suggesting
some residual KCC2 activity. Thus, the identiﬁed missense
changes in KCC2 render the transporter either near non-
functional (L426P and G551D) or partly functional (L311H),
and are predicted to lead to intracellular Cl accumulation in
neurons with loss of a hyperpolarizing driving force for
GABAARs and GlyRs.
Mutant KCC2 shows reduced expression/altered glycosylation.
To further investigate disease mechanisms in KCC2-associated
EIMFS, an in vitro heterologous expression system for
immunoblotting and surface protein biotinylation was used to
compare total and cell surface expression levels of wild-type and
mutant KCC2 (Fig. 4). When compared with wild-type, the
mutants L311H, L426P and G551D showed signiﬁcantly reduced
KCC2 expression at the cell surface versus total (whole-cell lysate)
expressed transporter (two bands representing glycosylated
and unglycosylated protein occur at B130 kDa, Fig. 4). The
proportion of wild-type KCC2 existing in the glycosylated state
was 50% at the surface and 43% in whole-cell lysate; signiﬁcantly
lower proportions were observed for all three mutants at both the
cell surface and in total cell lysates (Table 1). The missense
changes therefore appear to impair cell surface expression and
post-translational modiﬁcation of KCC2. To further investigate
the cell surface expression of KCC2 mutants, HEK 293 cells were
transfected with KCC2, FLAG-tagged at the second extracellular
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Figure 2 | Structural modeling of KCC2 mutants. (a) A homology model of KCC2 showing a transmembrane (TM) protein consisting of 12 TM helices
interconnected by intracellular and extracellular loops. (b) In our homology model, L426 (shown in a surface representation) is located in the unwound
TM6 (TM6a). This helix, together with TM1, is pivotal for the transporter function. In the L426P mutant, the substitution of a leucine with a proline
(not shown) is likely to introduce a kink in TM6, which will result in alternation of the interaction with TM1b. A comparative analysis of different structures
of transporters (LeuT, vSGLTand ApcTstructures) shows that the conformation of TM1b plays a key role in allowing access to the substrate binding pocket
(maintaining a conformation that completely occludes access to the post-synaptic space but only partially occludes access to the cytosolic side). Thus, the
presence of a proline in KCC2 TM6 could lead to an alteration of the extracellular occlusion formed by TM1b and TM6. (c) Our KCC2 model predicts that
G551 (shown in a surface representation) is located in the intracellular loop between TM8 and TM9 (residues 539–557). In the G551D mutant, the
substitution of the glycine with an aspartic acid—a larger and negatively charged amino acid—is likely to introduce a distortion in the orientation of TM8.
The latter helix contains the putative substrate binding residues A521 and S525, based on homology to ApcT (A287 and T291, respectively, PDB: 3GIA)35.
Therefore, introducing an aspartic acid in position 551 could lead to disruption of the binding site thereby affecting substrate binding.
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loop, and HcRed NLS, to visualize the cell nucleus and provide
conﬁrmation of effective transfection. Immunostaining of
permeabilised cells revealed that all three mutants were overall
expressed at similar levels to wild-type KCC2 (Fig. 5e–h).
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Figure 3 | Electrophysiology of wild-type and mutant KCC2. (a–c) KCC2 mutants exhibit a depolarized ECl. (a) Examples of I–V relationships in HEK293
cells transfected either with GlyR a2 alone (no KCC2), or GlyR a2 with a wild-type KCC2 construct. IGly amplitude was plotted against the holding potential
and the intercept of the line of ﬁt of this relation with the abscissa was taken as ECl. Superimposed traces show examples of glycine-evoked currents
recorded from individual cells at different holding potentials (–80 to þ 20mV). (b) Examples of I–V relationships in HEK293 cells co-transfected with GlyR
a2 and mutant KCC2, as indicated. ECl in mutant KCC2 is depolarized in comparison to wild-type (ﬁt of I–V relation indicated by dashed-line). Calibration
bars for 3a and 3b: 1nA, 1sec. (c) Summary chart plotting the distribution of ECl for each cell group: no KCC2: –14.7±0.8mV (n¼ 5), GlyR-KCC2:
–29±3.5mV (n¼ 9), G551D: –17.4±1.2mV (n¼ 5), L426P: –17.9±2.9mV (n¼ 5), L311H: –15±3.1mV (n¼ 9); *P¼0.006, one-way analysis of variance
(ANOVA). Grey symbols represent measurements from individual cells. Boxes represent the mean±standard error of the mean. GlyR a2: glycine receptor
a2, Wt-KCC2: wild-type Kþ-Cl co-transporter. (d–f) The rate of Cl extrusion is impaired in KCC2 mutants. (d) IGly amplitude plotted against time in a
HEK293 cell co-transfected with GlyRa2 and wild-type KCC2 and held at different membrane potentials as indicated in the top image. Vertical bars indicate
the times of successive glycine applications. Example traces show glycine-evoked currents at times indicated by letters in italic. Calibration bars: 1 nA,
300ms. (e) Rate of recovery of IGly amplitude after switching back the holding potential from þ40 to  80mV. Fine lines replace symbols and error bars
are omitted for legibility. An exponential decay function was used to ﬁt IGly amplitude ratio in each cell group. (f) Summary bar graph of the time-constant
of IGly recovery in each group (no KCC2: 224±56.7 s, n¼6; WT-KCC2: 59.5±7.7 s, n¼ 13; L426P: 162.5±42.1 s, n¼4; G551D: 340.1±137 s, n¼4; L311H:
88.1±11.5 s, n¼ 7). *Different from WT-KCC2 (Po0.01), ANOVA.
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Figure 4 | Immunoblotting studies for KCC2 mutants. Immunoblotting
studies including cell surface biotinylation and total cell lysate studies.
Two bands are observed for WT and the three mutant KCC2 proteins
closely located to each other at B130 kDa and corresponding to
glycosylated (upper band) and unglycosylated (lower band) states36.
Table 1 | Quantiﬁcation of total and glycosylated
sub-fraction of KCC2 at the cell surface and in whole cell
lysate.
Glycosylated plus unglycosylated
KCC2 at the surface (fraction of
total, % of wild-type)
Glycosylated KCC2
(% of glycoslyated
plus unglycosylated)
Surface
fraction
Total
fraction
WT 100±±0% 50±13% 43±1%
L311H 34±7%** 22±5%* 17±1%**
G551D 41±10%* 32±7% 38±1%*
L426P 55±13%* 10±3%** 16±4%*
WT, wild-type.
n¼4. *Po0.05, **Po0.005 (compared with WT, one-sample Student’s t-test).
All three mutants showed signiﬁcantly reduced levels of cell-surface over total expression of
KCC2 when compared with WTwith reduced levels of glycosylated KCC2 protein evident at the
cell surface and also in total cell lysates (Figure 4).
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However, while wild-type KCC2 was robustly detected at the
surface of intact cells, much less KCC2 was detected in cells
expressing KCC2-L311H, -L426P and -G551D (Fig. 5a–d),
further suggesting that these three mutations lead to expression
of mutant KCC2 transporters with impaired cell-surface
localization.
KCC2 knockout zebraﬁsh model reveals early motor deﬁcit. A
zebraﬁsh disease model was utilized to study the effect of KCC2
deﬁciency on circuit function at an early stage of development.
Zebraﬁsh have two KCC2 orthologs, KCC2a and KCC2b (due to
ancestral gene duplication) and TALEN-mediated genome editing
was undertaken to generate knockout zebraﬁsh models. An 8-bp
deletion was induced in exon 4 of KCC2a to disrupt KCC2a and
similarly, a 5-bp deletion was induced in exon 4 of KCC2b to
disrupt KCC2b. Wild-type zebraﬁsh larvae at 2 days post
fertilization (dpf), showed a typical escape swimming response
upon touch, with rhythmic side-to-side contraction of the trunk
(Supplementary Video 1). Neither single KCC2a nor KCC2b
knockout zebraﬁsh displayed developmental or motor defects,
and both survived into adulthood. A KCC2a-KCC2b double
knockout zebraﬁsh model was then generated, and tactile-
induced motor behaviour was assessed. In contrast to wild-type,
the KCC2a-KCC2b double knockout zebraﬁsh showed abnormal
jerky spasmodic movements during the escape response
(Supplementary Video 2). Severe motor phenotypes are also
reported in other loss-of-function KCC2 animal models. Null
mutations in Kazachoc (Drosophila ortholog of KCC2) lead to
lethality, while partial loss-of-function causes increased seizure
susceptibility mediated by GABAA receptor dysfunction.13
Complete knockout of kcc2 in mice also leads to neonatal
lethality14. A murine model retaining B5% KCC2 function
displays frequent spontaneous seizures and excess hippocampal
excitability15. Mice with one null and one hypomorphic allele
resulting in 15–20% overall residual KCC2 protein have an
increased susceptibility to induced seizures with abnormal
cognitive function16. Overall, our data suggests that, as evident
in a number of other animal models, loss of KCC2 function
causes an early motor deﬁcit in zebraﬁsh, characterized by jerky
spasmodic movements. While the double knockout zebraﬁsh may
represent a useful model for EIMFS, true comparability to the
human disease is limited by genetic and biological differences
between the two model systems.
KCC2 in epilepsy and other neurological disorders. The
physiological role of KCC2 in mediating neuronal inhibition has
led to considerable speculation about the potential involvement
of this transporter in the pathogenesis of human epilepsy17.
Our report of autosomal recessive loss-of-function SLC12A5
mutations in EIMFS substantiates this hypothesis. A role for
KCC2 in human epilepsy is further evident by the recent
identiﬁcation of heterozygous missense SLC12A5 polymorphisms
in other epilepsy phenotypes, as R952H and R1049C exhibit
statistical association with idiopathic generalized epilepsy18.
These variants reside in conserved residues in the KCC2
cytoplasmic C-terminus and display reduced Cl(-)-extrusion
capacities leading to less hyperpolarized glycine equilibrium
potentials (EGly), and impair KCC2 stimulatory phosphorylation
at serine 940, a key regulatory site. Furthermore, R952H has been
reported in an Australian family with febrile seizures19, and
KCC2-R952H reduces neuronal Cl extrusion with impaired
ability to induce dendritic spines. Reduced surface expression of
KCC2-R952H is postulated to contribute to these functional
deﬁcits19. Pathogenic processes governing KCC2-related seizure
disorders therefore appear multifactorial, with mechanistic
overlap between the different epilepsies. Impaired KCC2-
mediated chloride extrusion (Fig. 6) from defective transporter
activity, decreased cell-surface KCC2 expression and reduced
protein glycosylation contribute to loss of KCC2 function in the
severe early-onset epileptic encephalopathy described in this
report. Developing novel therapeutic molecules that increase the
expression and efﬁcacy of KCC2 for early clinical translation are
now a research priority. Genotype-phenotype correlations will
become evident over time, as more cases are reported, but
SLC12A5 gene dosage (recessive versus dominant disorders),
mutation type and the effect of mutations on protein activity may
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indeed inﬂuence epilepsy phenotype, including age of disease
onset and clinical severity. Identiﬁcation of additional SLC12A5
mutations in humans will no doubt further expand the clinical
spectrum and solidify genotype-phenotype observations in
KCC2-related human diseases.
Methods
Subject recruitment. Family A was enrolled in a Swedish study investigating EIEE
with exome sequencing at the Karolinska University Hospital. Family B was
recruited to a United Kingdom EIMFS genetic study from Royal Manchester
Children’s Hospital. In addition, patients with EIMFS (without mutations in
known disease genes) were identiﬁed through international collaborators. This
included 18 UK patients, 1 Swedish patient, 7 patients from the USA and 12
patients from an Australian cohort. Detailed electroclinical phenotyping was
performed in all cases. Written informed consent was obtained from participants,
and all studies were approved by local ethics committees (The Regional Ethical
Review Board in Stockholm, Sweden and South Birmingham Research Ethics
Committee, UK) and performed in accordance with the Declaration of Helsinki.
Whole exome sequencing data were anonymised and deposited in secure databases
at each participating academic institution with data access to members of the
research teams involved in each study. Consent given by participants did not
extend to public access of the sequence data given the risk of patient conﬁdentiality
issues.
SNP array studies. Family B comprised two affected brothers born to ﬁrst
cousin parents so homozygosity mapping was undertaken. SNP genotyping was
performed using Illumina cytoSNP-12 (Illumina Inc., San Diego, CA, USA). Both
parents, two affected children and the two unaffected children were analysed.
Genotypes were generated using GenomeStudio (Illumina Inc.) and then analysed
manually using Microsoft Excel and also using BEDTools20.
Exome sequencing. For exome sequencing, 2–5 mg of genomic DNA from Patients
A-II:1, A-II:2, and both parents and B-II:4 was used to prepare paired-end libraries
using TruSeq chemistry according to standard protocols (Illumina Inc.). Exome
enriched libraries were made using the in-solution Nimblegen SeqCap EZ Exome
Library (Roche Nimblegen Inc., Madison, WI, USA), Agilent SureSelect version 5
(Agilent) or standard protocols supplied by Illumina. Exome enriched DNA
libraries were sequenced, 2 101 bases on a HiSeq 1000, 2000 or 2500 sequencing
system (Illumina Inc.).
In Family A, bioinformatic analysis was performed using the Mutation
Identiﬁcation Pipeline (MIP) v.1.5.6 http://mip-api.readthedocs.org/en/latest/
index.html. The data were annotated, scored and ranked using MIP. MIP annotates
the variants with information from external and in-house databases as well as the
genetic inheritance pattern (including compound mutations; Supplementary
Table 2). A weighted sum model based on a subset of these annotations is then
applied to generate a rank score for each variant. The variants are then sorted
according to disease causing potential based on the rank score. Most weight in the
rank score model is put on the inheritance pattern, minor allele frequency, gene
coding annotation, functional annotation and protein predictions. Thus, MIP
retains all variants but prioritizes them according to disease causing potential based
on the rank score. Brieﬂy, the sequence reads were aligned to the whole human
genome reference GRCh37 using Mosaik (v.2.2.3) and PCR and optical duplicates
were marked using PicardTools (Picard 2013, http://picard.sourceforge.net:).
GATK package21,22 v.2.8-1 performed realignment, base recalibration, variant
identiﬁcation, recalibration and genotyping. Annovar23 v2013-08-23 annotated the
variants and MIPs custom scripts ranked them according to pathogenic potential.
All variants were loaded into Scout v.1.0 hosted at Science for Life Laboratory,
Stockholm, for clinical evaluation.
In Family B the sequencing data were mapped to the canonical chromosomes
(chr1-22, X, Y and M; UCSC genome browser) of the hg19 (GRCh37) reference
human genome using the Novoalign Software. After removal of PCR duplicates
(MosaikDupSnoop/Picard) and reads without a unique mapping location
(MosaikSort), quality score recalibration and indel realignment were performed
using the GATK package21,22. Variants were extracted using the Maq model in
SAMtools24 and ﬁltered by the following criteria: coverage 48 , consensus
quality430, SNP quality430 and root mean square mapping quality430. These
variants were further ﬁltered against dbSNP build 135 and 1000 Genomes and
annotated based on the UCSC known Canonical transcript database (UCSC
genome browser) using Annovar. Genes containing non-synonymous or splice-site
variants or coding indels were considered further. Due to the family structures for
both families, we employed an autosomal recessive model, and genes containing
one or more homozygous variants (Family A and B) or two or more heterozygous
non-synonymous, splice-site or coding indels variants (Family A) were considered
candidate genes. The candidate genes left after ﬁltering were investigated for
putative involvement in EIMFS by literature and database searches.
Direct sanger sequencing. Sanger sequencing was used to conﬁrm the variants
identiﬁed on exome sequencing and establish segregation within each family.
Primer pairs were designed for all 26 coding exons and exon/intron borders of
SLC12A5 for both transcripts ENST00000243964 and ENST00000454036
(www.ensembl.org). Experimental conditions (including primer sequences) are
available on request. Sequencing reactions were run on an ABI PRISM 3730 or
130xl DNA Analyzer (Applied Biosystems Inc.).
Molecular genetic screening of additional patients. EIMFS patients (total
n¼ 38) were also screened for SLC12A5 variants, either by direct sequencing
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(n¼ 14) or by analysis of pre-existing exome sequencing data (n¼ 24). SLC12A5
was screened in additional patients with EIEE who did not ﬁt the electroclinical
criteria of EIMFS (n¼ 11).
Homology modelling of KCC2. Fold recognition of KCC2 was performed with
HHPRED25. The crystal structure of the Methanocaldococcus jannaschii ApcT
Transporter (PDB: 3GIA; 2.35Å resolution) was identiﬁed as the best template for
residues 115–682 (TM middle domain), (HHPred e-value: 2.4 10 36). The
HHpred alignment was used as preliminary pairwise sequence alignment for
homology modelling. The extended loop region between TM5 and TM6 (residues
303–407) could not be accurately modelled due to lack of sequence identity and
was therefore removed. A preliminary homology model of KCC2 middle domain
was calculated using MODELLER-9v1026. The ConSurf web server27 with default
parameters, was used to evaluate the evolutionary conservation and improve the
quality of the alignment accordingly. This alignment was then used to create 1,000
homology models that were further assessed with the DOPE statistical potential
score28. The model based on the lowest score (Normalized DOPE z-score:  0.464)
was selected. In addition, evaluation using the ProSA web server showed that the
model quality (Z-score¼  2.63) fell within a range typically found for native
proteins of similar size29. Next, selected non-synonymous substitutions were
modelled into the KCC2 homology model with the swapaa command in Chimera30
using the Dunbrack backbone-dependent rotamer library31 and taking into
account the lowest clash score, highest number of H-bonds and highest rotamer
probability.
Cell culture and transfection for electrophysiology. An expression vector
(pCMV6-XL5) containing the full-length human SLC12A5 cDNA was obtained
from Origene, USA and validated by Sanger DNA sequencing. Cell-based cloning
into a pRK5 expression vector (courtesy of Professor R. Harvey) using custom-
designed cloning primers (Supplementary Table 4a) was successful for the
wild-type DNA and for one of the mutations, For the remaining two mutations,
custom-designed mutagenesis primers (Supplementary Table 4b) and a Quik-
Change II site-directed mutagenesis kit (Agilent Technologies, USA) were utilized.
Plasmids containing each of the three mutations were thus generated32. Sanger
sequencing was performed to ensure only the desired mutations had been
introduced. HEK293 (ATCC CRL-1573, ATCC, Middlesex, UK) cells were
transiently co-transfected (Lipofectamine) with plasmids encoding GFP, the human
GlyR a2 subunit and equal amounts of WT, L311H, L426P or G551D KCC2.
Electrophysiology. Patch pipettes (3–5MO) were pulled from borosilicate glass
(1.5-mm outer diameter, 0.5-mm wall thickness) and recordings were obtained
from eGFP-positive HEK293 cells under infrared differential interference contrast
imaging. The perfusion solution contained (in mM): NaCl (140), KCl (4), MgCl2
(1), CaCl2 (2), D-glucose (5), HEPES (10) (pH 7.2, osmolarity 298mOsm.l–1).
Currents were recorded with a Multiclamp 700-B ampliﬁer (Molecular devices),
ﬁltered at 2 kHz (internal four-pole low-pass Bessel ﬁlter) and sampled at 10 kHz.
The access resistance, monitored throughout the experiments was o15MO and
results were discarded if it changed by more than 20%. The pipette solution
contained (in mM): CsCl (50), NaCl (10), CsF (60), EGTA (20), HEPES (10)
(pH 7.2, osmolarity 310mOsm.l–1). Local pressure application of glycine
(1mM in control HEPES solution) was delivered via a patch pipette connected to a
Picospritzer (General Valve Corporation). The puff pipette was positioned roughly
10–20 mm away from the recorded cell and the bath perfusion arranged to keep it
downstream of this position. Cells were ﬁrst held at –80mV while several glycine
applications were made at 30 s intervals to ensure that no desensitisation occurred.
Glycine puffs (3–5ms, 5–10 psi) were then delivered every minute at different
holding potentials (–80 to þ 20mV, 20mV increment). A linear regression of IGly
amplitude plotted against the holding potential was used to analyse the voltage
dependence. The intercept of the I–V relation with the abscissa was then extra-
polated as ECl. (As experiments were performed in bicarbonate-free solution
buffered with HEPES IGly was solely mediated by Cl and thus we report ECl).
ECl predicted from the Nernst equation was  21.3mV. Data are expressed as
mean±s.e.m and were considered signiﬁcant if Po0.05.
Immunoblotting studies. The full-length human wild-type KCC2 and the three
mutant KCC2 sequences were cloned into the mammalian expression vector,
pCMV–Myc. We ampliﬁed the sequences from the Origene KCC2 wild-type
expression vector and the mutagenized vectors using the Platinum Taq DNA
Polymerase High Fidelity (Life Technologies), custom-designed cloning primers
(available on request) and 94 C for 2min followed by 30 cycles of 94 C for 30 s,
55 C for 30 s and 68 C for 3min 30 s. Then using the QIAquick Gel Extraction Kit
(QIAGEN) puriﬁed PCR products and the pCMV–Myc plasmid were successively
digested ﬁrst with EcoRI and then with Acc65I (isoschizomer of KpnI) according to
manufacturer’s protocol. Following puriﬁcation with the QIAquick Gel Extraction
Kit the PCR products were ligated into the EcoRI and KpnI sites of the vector
pCMV-Myc (which was kindly provided from Dr Paul Gissen) using T4 DNA
ligase (Promega). For ampliﬁcation of Myc-tagged KCC2 constructs we trans-
formed NEB 10-beta competent E.coli cells (New England BioLabs) with the
plasmids and subsequently isolated the plasmids with the QIAGEN Plasmid Maxi
Kit (QIAGEN). All expression constructs were conﬁrmed by Sanger sequencing of
the entire coding region, to ensure that during PCR ampliﬁcation no additional
mutations had been introduced. LLC-PK cells (non-transfected LLC-PK1 cells
kindly supplied by Dr Roxanne A. Vaughan, University of North Dakota) were
then transiently transfected with equal amounts of WT, L311H, L426P and G551D
constructs. After 24 h, surface proteins were labelled with biotin and cells were
lysed. Biotinylated fraction and total cell lysates were eluted with 8% Tris-glycine,
separated on a SDS polyacrylamide gel, transferred to nitrocellulose membrane and
blotted with anti-myc antibodies. Control beta-actin bands were observed in the
total cell lysate but not in the biotinylation assay (Fig. 4). Densitometric analysis
with NIH Image J yielded Area-Under-Curve (AUC) for each western blot band.
An uncropped immunoblot is included as Supplementary Figure 3. Two analyses
were undertaken to determine the effect of mutations (Table 1):
1. Calculation of cell-surface KCC2 relative to the total level of KCC2 and
normalization with WT values. In this analysis both bands are taken together for
both surface and total expression, assuming full and equal recovery through
biotinylation steps in work-up ðsurfacetotal Þ ¼ AUC glycoþ deglycoð ÞsurfaceAUCðglycoþ deglycoÞtotal
2. Calculation of the fraction of glycosylated state in the cell-surface (1), or total
expression, (2):
ð glyco
glycoþ deglycoÞsurface ¼ ð
AUC glycoð Þsurface
AUCðglycoþ deglycoÞsurfaceÞ ð1Þ
ð glyco
glycoþ deglycoÞtotal ¼ ð
AUC glycoð Þtotal
AUCðglycoþ deglycoÞtotalÞ ð2Þ
Immunostaining and confocal microscopy. HEK293 cells were transfected with
pCAGGS-KCC2-FLAG33 (gift from S. Levi, Institut National de la Sante´ et de la
Recherche Me´dicale, Paris, France), pCAGGS-KCC2-FLAG-L311H, pCAGGS-
KCC2-FLAG L426P or pCAGGS-KCC2-FLAG G551D and HcRed NLS using
FuGENE (Promega). After 24 h, cells were ﬁxed in 4% (w/v) paraformaldehyde in
phosphate buffered saline (PBS) for 15 s, washed with PBS, incubated with 50mM
NH4Cl for 10min, washed with PBS and blocked for 30min in PBS supplemented
with 2% (w/v) bovine serum albumin (BSA) and 10% (v/v) goat serum. Total
KCC2-FLAG in cells was assessed by the addition of 1% (v/v) Triton X-100 to
blocking media. Cells were incubated for 1 h with rabbit anti-FLAG antibody
(1:200; Sigma, catalogue number F7425) in PBS with 2% BSA, washed in PBS,
incubated with AlexaFluor 488-conjugated goat anti-rabbit antibody (1:600;
Invitrogen, catalogue number A-11008) in PBS-BSA, washed with PBS and
mounted on slides. Images were collected using a Zeiss LSM 710 confocal
microscope using  63 objective.
Zebraﬁsh models and behavioural analysis. Zebraﬁsh (Danio rerio, AB strain)
obtained from the Zebraﬁsh International Resource Center (Eugene, OR) were
maintained at 28.5 C following established procedures. The experiments were
performed in accordance with the approved guidelines of the Committee on
Animal Use and Care at the National Institute of Genetics, Japan. Zebraﬁsh have
two KCC2 orthologs (KCC2a and KCC2b), due to an ancient gene duplication.
TALENs for zebraﬁsh KCC2a and KCC2b were designed to target the fourth exon
of both KCC2a and KCC2b genes. To construct TALEN plasmid, TAL effector
repeats were assembled in pFUS plasmid by BsaI (New England Labs) digestion
and following T4 DNA ligase reaction were subsequently subcloned into pCS2þ
vector using BsmBI (New England Labs) restriction sites34. The TALEN constructs
were linearized by NotI digestion and used for in vitro transcription. Capped RNAs
were synthesized using mMESSAGEmMACHINE SP6 kit (Life Technologies)
according to the manufacturer’s instruction. TALEN RNAs (200 pg for each
TALEN) were injected into 1-cell stage zebraﬁsh embryos and gene disruption of
KCC2a (8 bp deletion) and KCC2b (ﬁve base deletion) (Supplementary Data 1) was
conﬁrmed by sequencing the F1 ﬁsh. KCC2a-KCC2b double knockout larvae were
obtained by crossing double heterozygous carrier ﬁsh. Genotyping was done using
following primers and PCR products were separated by 15B20% polyacrylamide
gel electrophoresis.
KCC2a (genotyping, forward): 50-TGGGTGTGTACCTGCCC-30 KCC2a
(genotyping, reverse): 50-CCTGAGGAATAGAATCACACCC-30 KCC2b
(genotyping, forward): 50-CGTTTACCTACCATGTCTTCAAAACAT-30
KCC2b (genotyping, reverse): 50-CCAGGTCATCCTGAGGAACAAA-30 At 2 days
post fertilization, the embryonic behaviour of the wild-type and KCC2a-KCC2b
double knockout embryos (both male and female, 10 per group) were investigated
by a tactile response assay in which mechanosensory stimulation was applied to the
tail. The response was recorded using a dissection microscope (MZ16, Leica) and a
high-speed CCD camera (HAS-220, Ditect).
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